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1. Introduction 
The endothelium is a functional barrier composed of a single layer of endothelial cells 
between the vessel wall and circulating blood. The human vascular bed has a combined 
surface area of 1000 m2 and contains 1013 endothelial cells. The endothelium is the largest 
endocrine organ, with also important paracrine and autocrine functions (Perry & Pearson, 
1989). Endothelial cells play important roles in haemostasis, vasoactivity, cellular 
proliferation, immunological reactions and inflammatory events. Therefore, endothelial 
dysfunction can lead to vasoconstriction, local ischemic phenomena and hypertension, 
thrombus formation and plaque growth and rupture, vascular proliferation and remodeling, 
and immunologic inflammation processes. Risk factors for endothelial dysfunction include 
old age, hypertension, diabetes mellitus, hypercholesterolemia, tobacco, menopause, male 
gender and obesity (Müller & Griesmacher, 2000; Raitakari & Celermajer, 2000).    
Cardiovascular disease is the leading cause of mortality in dialysis patients. In large cross- 
sectional studies of dialysis patients, traditional cardiovascular risk factors such as 
hypertension and hypercholesterolemia have been found to have low predictive power, 
while markers of inflammation and malnutrition are highly correlated with cardiovascular 
mortality. However, the pathophysiology of the disease process that links uremia, 
inflammation, and malnutrition with increased cardiovascular complications is not well 
understood. In uremia, endothelial dysfunction derives from a systemic altered milieu that 
is partially aggravated by the dialysis treatment itself. From water quality to the type of 
membrane employed, many artificial factors intervene that trigger inflammatory processes 
culminating with endothelial damage, smooth muscle cell hyperplasia, fibrosis and vascular 
calcification. 
The underlying vascular disease consists mainly of two types, arteriosclerosis and 
atherosclerosis. Arteriosclerosis is mainly characterized by premature arterial aging with 
loss of elastic fibers and increased stiffness. Atherosclerosis is characterized by intima-media 
thickening, plaque formation and luminal narrowing. Both processes may interact 
simultaneously, possibly via diverse mechanisms, as endothelial dysfunction, shear stress, 
and elastic fiber fragmentation (Fishbein & Fishbein, 2009; Guérin et al., 2008; London & 
Drüeke, 1997).  
Endothelial dysfunction is a well-documented early phenomenon in atherosclerosis that 
precedes structural changes and clinical manifestations, particularly in dialysis patients 
(Frick & Weidinger, 2007). Decreased endothelial function is thought to primarily reflect a 
decreased bioavailability of nitric oxide, a critical endothelium-derived vasoactive factor 
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with vasodilatory and anti-atherosclerotic properties (Tatematsu et al., 2007). Although 
endothelial dysfunction is common as renal function declines, the exact causes are not 
known. The effects of various uremic toxins on endothelial dysfunction and cardiovascular 
outcome are being studied. There is also growing evidence that asymmetric 
dimethylarginine, an endogenous inhibitor of nitic oxide-synthase, is involved in mediating 
endothelial damage and dysfunction (Kielstein & Zoccali, 2005), is primarily cleared by the 
kidney, is elevated in chronic kidney disease and is associated with poor prognosis in 
dialysis patients (Stenvinkel et al., 2008).  
Increased oxidative stress is an outstanding culprit in the process of increased atherogenesis 
and cardiovascular morbidity and mortality found in the dialysis population. Vascular and 
endothelial complications accelerate as renal function is progressively decreased in the pre-
dialysis population, which is potentiated in chronic kidney disease Stage 5. Increasing 
number of biomarkers are constantly emerging as potential culprits in this process of 
accelerated atherogenesis and thrombosis in haemodialyzed subjects (Himmelfarb et al., 
2002). 
Oxidative stress, endothelial dysfunction, inflammation, protein-energy wasting, 
sympathetic activation, haemostatic disturbances, endocrine disturbances, uremic retained 
toxins, vascular calcification and ossification, infections, anemia and its therapy, and certain 
haemodialysis components  are amongst the main uremia-related biochemical risk factors in 
patients on dialysis (Stenvinkel et al., 2008). Increased levels of oxidative stress markers are 
present in the plasma of chronic kidney patients, which indicates that uremia is a pro-
oxidant state (Himmelfarb et al., 2002). Oxidative stress seems to occur early in kidney 
disease evolution because oxidative markers have been documented at least as early as stage 
3 (Oberg et al., 2004). Moreover, dialysis treatment seems ineffective in the correction of 
oxidative stress and may sometimes trigger oxidant processes, although recent data may 
show the opposite (Pupim et al., 2004; McGregor et al., 2003). 
There exists an activated inflammatory response in 30-50% of patients with end-stage renal 
disease (Zimmermann et al., 1999), even before dialysis is started: C-Reactive protein levels, 
one of the non-specific but highly sensitive markers usually employed to assess 
inflammation, may also be raised by persistent infections; comorbidities as chronic heart 
failure or chronic angina; accumulation of oxidative stress by-products; and pro-
inflammatory cytokines retained in uremia (Stenvinkel, 2001a). Chronic inflammation, 
mediated by pro-inflammatory cytokines and acute-phase reactants, may contribute to 
accelerated atherosclerosis (Stenvinkel, 2001a). Normal endothelial function is crucial for 
cardiovascular homeostasis. Endothelial dysfunction results in lipid accumulation at the 
vessel wall, smooth muscle proliferation, and vasospasm and is associated with 
inflammation in advanced chronic kidney disease patients (Stenvinkel, 2001b). Finally, 
endothelial dysfunction and inflammation is associated with oxidative stress, leading to 
atherosclerosis and tissue hypoxia (Handelman et al., 2001).  
Vascular calcification and ossification, present in 30% to 70% of chronic kidney patients, is 
virtually always associated with dialysis due to both arterial intima and media disturbances, 
plaque formation, hypertension and atherogenesis (Sigrist et al., 2006; Schwarz et al., 2000), 
and is related to arterial dysfunction because it alters nitric oxide-dependent vasodilatation 
and increases pulse-wave velocity in dialysis patients (Raggi et al., 2007). Calcium, 
hyperphosphatemia and hyperparathyroidism are risk markers of vascular calcification, and 
vitamin D deficiency is associated with increased mortality and cardiovascular disease 
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(Block et al., 2005). An antagonist of vascular calcification, fetuin-A, is low in dilaysis 
patients and is associated with increased cardiovascular mortality (Ix et al., 2007). 
Emerging evidence suggests that aberrant DNA methylation may play a deleterious  role in 
atherosclerosis and endothelial dysfunction (Dong et al., 2002). DNA methylation changes 
occur during atherogenesis and may contribute to lesion development. The homocysteine 
precursor S-adenosylmethionine is a competitive inhibitor of S-adenosylmethionine 
methyltransferases and is increased in haemodilaysis patients. This phenomenon leads to 
unbalanced methylation in the setting of hyperhomocysteinemia. In vascular disease 
patients increased homocysteine and S-adenosylmethionine concentrations are associated 
with DNA hypomethylation (Castro et al., 2003; Valli et al., 2008). In this regard, the 
presence of inflammation may partly contribute to an association between homocysteine 
levels, endothelial dysfunction and cardiovascular outcome in dialysis subjects, resulting in 
part in aberrant DNA methylation (Stenvinkel et al., 2008; Teitell & Richardson, 2003). 
Finally, endothelial cells modify their function in response to changes in the extracellular 
concentration of sodium and potassium, constantly present in dialysis patients. The control 
of local tissue perfusion that the endothelium exerts may play an important in vascular tone 
and the development of hypertension and atherosclerosis (Oberleithner et al., 2010). 
2. The endothelium in normal conditions 
The endothelium is a functional and anatomic barrier composed of a single layer of 
endothelial cells between the vessel wall and blood. The human vascular bed contains 1013 
endothelial cells, constituting our largest endocrine organ (Perry & Pearson, 1989). 
Endothelial cells play important roles in vascular tone, haemostasis, cellular proliferation, 
immunological processes and inflammatory events. The normal endothelium regulates 
vascular smooth muscle tone; exerts anticoagulant, fibrinolytic and antithrombotic actions; 
is involved in lipid, lipoprotein and eicosanoid metabolism; is a selective barrier for the 
normal trafficking of molecules from the interstitial tissue to the blood stream and viceversa, 
and contributes to vascular growth, leukocyte adhesion, and immunological processes. 
2.1 Regulation of vascular tone 
The endothelium releases a wide variety of substances both vasodilators and 
vasoconstrictors. Relaxing factors consist primarily of nitric oxide, prostacyclin, 
hyperpolarizing factor, bradykinin, and adrenomedullin. Constricting factors include 
mainly endothelin-1, thromboxane A2, prostaglandin H2, angiotensin II and free radicals. 
Amongst the relaxing molecules, nitric oxide constitutes the basis of endothelium-related 
vasorelaxation. Nitric oxide is synthesized by nitric oxide synthase from the N-terminal of 
L-arginine guanidine, is an unstable molecule with a half-life of a couple of seconds. There 
are three forms of nitric oxide: type I or neuronal, type II or inducible, and type III or 
endothelial, which is specific to the endothelium. Nitric oxide synthase is stimulated by 
nicotinamide dinucleotide (phosphate) (NADPH) and 5,6,7,8-tetrahydrobiopterin and 
inhibited by powerful oxidants as superoxide anions and hydrogen peroxide (Verma & 
Anderson, 2002). Excess inducible nitric oxide caused by many inflammatory cytokines such 
as tumor necrosis factor-alpha, interleukin-1 or -6 results in an exaggerated vasodilatation, 
whilst interleukins-4, -8, -10 and transforming growth factor-beta decrease nitric oxide 
expression (Webb & Vallance, 1997). Endothelial cells release nitric oxide into the 
www.intechopen.com
 
Special Problems in Hemodialysis Patients 
 
170 
surrounding smooth muscle cells of the vascular wall in a paracrine manner, causing 
vasodilatation and inhibiting their growth, and into the vascular lumen, impeding local 
platelet and leukocyte adhesion (Vanhoutte et al., 1997). One of the most important causes 
of endothelial nitric oxide release is shear stress. The physical stimulus of a faster or a 
pulsatile blood flow in the arterial wall leads to vasodilatation. Endogenous substances that 
stimulate nitric oxide release are catecholamines, vasopressin, bradykinin, histamine, 
serotonin, ADP and thrombin. The interaction between the normal endothelium and 
platelets is crucial for vascular tone stability and haemostasis. 
Amongst the vasoconstrictors produced by endothelial cells, endothelin plays an important 
role. Endothelins are 21-aminoacid peptides classified as 1 to 3, with a half-life of 
approximately 2 minutes and are derived from proendothelin in a reaction catalyzed by 
endothelin converting enzyme. Endothelin-1 is specific to the endothelium, is released 
paracrinally towards the vascular wall where it exerts its powerful vasoconstrictor effect on 
the smooth muscle cells (Yanashigawa et al., 1988; Clozel & Fischli, 1989). The most potent 
regulator of endothelin-1 production and release is blood flow. An increase in blood flow 
results in vasodilatation due to the activation of shear stress receptors in the endothelial 
cells, which increases nitric oxide synthesis and release and reduces endothelin-1 
production (Webb & Vallance, 1997). Other endothelin-1 stimulants include hypoxia, 
angiotensin-II, insulin, thrombin, low-density lipoproteins, vasopressin, transforming 
growth factor-beta and plasminogen activator inhibitor-1 (Webb & Vallance, 1997). The 
vasoconstrictor and proliferative action of endothelin-1 on vascular smooth muscle cells is 
mediated by A receptors, mainly in large vessels. When B receptors are activated, they also 
mediate vasoconstriction in small arteries and in the low-pressure venous bed. Endothelial B 
receptors, however, participate in other effects: clearance of circulating endothelin-1, 
inhibition of endothelin-1 synthesis, and paradoxically can also stimulate endothelial nitric 
oxide synthase activity, leading to vasodilatation and antiproliferative effects. (Webb & 
Vallance, 1997). 
2.2 Regulation of haemostasis 
The endothelial layer affects platelet function, plasma coagulation, and fibrinolysis. The 
physiologic role of the endothelium is to provide an antithrombotic surface; when 
endothelial damage occurs, the endothelium is converted into a prothrombotic layer (Cines 
et al., 1998). Factors with procoagulant effects on endothelial cells include reactive oxygen 
species, oxidized lipids, shear stress and slow blood flow, inflammation, age and certain 
hormones (Müller & Griesmacher, 2000). Moreover, the endothelium itself produces, 
according to the circumstances, both anticoagulant and procoagulant factors. The former 
action is mediated mainly by nitric oxide, prostacyclin, tissue plasminogen activator, 
thrombomodulin and antithrombin III, while the latter is starred by platelet activating 
factor, tissue factor, endothelin, thrombin, plasminogen activator inhibitor-1 and factor VIII. 
Coagulation itself results not only in thrombosis, but also stimulates inflammation and 
cellular growth. In fact, thrombin is involved in coagulation, anticoagulation, pro-
inflammatory and anti-inflammatory processes, cell adhesion and proliferation. Indeed, 
there is a strong association between inflammation and coagulation at the cellular level 
(Esmon, 1999). The physiology of haemostasis, inflammation and thrombosis, involves 
adhesion of leukocytes and platelets suspended in flowing blood to the vessel wall. Recent 
findings underscore the importance of blood flow and of exposed vessel wall structures in 
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these processes. Platelet-dependent haemostasis at injured vessel walls is more extensive at 
higher shear. However, leukocyte adhesion to endothelium increase at slow shear (Kuijper 
et al., 1996; Mackay & Imhof, 1993). Multiple receptor-ligand interactions are usually needed 
for attachment. Endothelial secreted selectins are first released, which interact with platelets 
for their adhesion and for platelet and endothelial synthesis of integrins. This process results 
in the recruitment of leukocytes through the action of intracellular adhesion molecules, 
vascular cell adhesion molecules and platelet endothelial cell adhesion molecules (Mulvihill 
et al., 2002). The next step is the migration of leukocytes to the subintimal space and later to 
the medial layer, where they interact with smooth muscle cells, fibroblasts and macrophages. 
This platelet-bridged action for leukocyte entrance into the vascular wall is independent of 
blood flow speed and shear (Mackay & Imhof, 1993). Finally, endothelial cells affect 
fibrinolysis synthesizing fibrinolyic factors and fibrinolysis inhibiting factors: Urokinase, 
tissue plasminogen activator, and plasminogen activator inhibitor. Briefly, tissue 
plasminogen activator is released from endothelial cells and cleaves plasminogen to form 
plasmin, a potent fibrinolytic substance in a fine physiological balance with plasminogen 
activator inhibitor-1, a protein also released from endothelial cells that antagonizes tissue 
plasminogen activator. The levels of both molecules are increased as a result of excess 
stimulation of endothelial cells by thrombin or as a result of endothelial dysfunction (Huber, 
2001; Kuijper et al., 1996). 
3. The endothelium and chronic kidney disease 
Patients with end-stage renal disease are at high risk of developing cardiovascular disease 
and decreasing their life survival. Renal insufficiency may be part and/or cause of a 
systemic subclinical atherothrombotic process (Stam et al., 2003). As mentioned before, 
arteriosclerosis can contribute to atherosclerosis and vice versa, possibly through 
endothelial dysfunction, biomechanical and blood flow stress to endothelial cells, and elastic 
fragmentation (Guérin et al., 2008). Both processes can ultimately lead to vascular 
calcification and ossification, clinically assessed as an increase in arterial stiffness and 
hypertension (McEniery et al., 2009). Accelerated atherogenesis at any stage of chronic 
kidney disease may be due to the interplay of traditional and nontraditional risk factors, 
such as asymmetric dimethylarginine, homocysteine, advanced glycation end products, 
endothelial lipidosis, oxidative stress processes and inflammatory molecules (Goligorsky, 
2007). Therefore, it is correct to consider endothelial dysfunction as a heterogenous 
syndrome, which can be focused either as a local or a systemic condition, as in chronic 
kidney disease; with subclinical or clinical manifestations; being reversible or irreversible 
according to its severity; and with many related etiologic mechanisms, as already mentioned 
(Goligorsky, 2007). In chronic kidney disease, endothelial dysfunction is characterized by 
increased plasma concentrations of endothelium-derived molecules, an imbalance between 
circulating endothelial cell and bone-marrow endothelial progenitor cells, or reduced 
endothelium-dependent vasodilatation (van Guldener et al., 1997; Rabelink et al., 2010). As 
renal function deteriorates, an atherogenic milieu generates due to the accumulation of 
uremic toxins with direct impact on the endothelium and the vessel wall, contributing to 
oxidative stress and enhancing a subclinical inflammatory state. In chronic kidney disease, 
these initial steps in endothelial dysfunction may perpetuate if not identified at the early 
subclinical stages, leading to atherogenesis (Ross, 1999). Decreased endothelial function is 
thought to primarily reflect a decreased bioavailability of nitric oxide, a molecule with 
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vasodilatory and antiatherosclerotic properties (Tatematsu et al., 2007). Asymmetric 
dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is involved in 
atherogenesis, is primarily cleared by the kidney and is elevated in kidney disease (Kielstein 
& Zoccali, 2005). Dimethylarginine is considered as an independent predictor of endothelial 
dysfunction and poor outcome in dialysis patients (Zoccali et al., 2001).  
Albuminuria is another predictor of increased cardiovascular risk (de Zeeuw, 2007). 
Albuminuria is also associated with other cardiovascular risk factors, such as abnormalities 
in fibrinolysis (Annavekar & Pfeffer, 2004), inflammation (Festa et al., 2000), and 
dyslipidemia (Tonelli & Pfeffer, 2007). Although the nature of the links between 
albuminuria and vascular disease may partly be due to endothelial dysfunction, persistent 
low-grade inflammation also plays a role. Indeed, inflammation is associated with both 
endothelial dysfunction (Stenvinkel, 2001b) and albuminuria (Festa et al., 2000). 
Noteworthy, albeit frequently present, proteinuria seldom is considered as a cause of 
inflammation, protein-energy wasting and endothelial dysfunction in hemodialysis. 
Albuminuria is strongly associated with increased levels of pentraxin-3, an inflammatory 
mediator produced by a variety of tissues and cells, mainly endothelial cells, macrophages 
and adipocytes, in response to proinflammatory signals (Abderrahim-Ferkoune et al., 2003; 
Mantovani et al., 2006). Pentraxin-3 is elevated in dialysis subjects (Boehme et al., 2007) and 
is being considered as a new mortality risk factor in dialysis patients (Tong et al., 2007). This 
suggests that it may have an additional role in the atherogenic process to common 
inflammatory mediators (Stenvinkel et al., 2008). Because of its extrahepatic synthesis, 
pentraxin-3 levels are believed to be an independent indicator of disease activity directly 
produced at sites of inflammation and linked to endothelial dysfunction.  
Detached circulating endothelial cells may serve as potential markers of endothelial damage 
in kidney disease (Koc et al., 2005). These circulating endothelial cells include endothelial 
progenitor cells, which are bone marrow–derived, and inflammatory endothelial cells, 
which are thought to be detached from the vessel walls and enter the circulation as a result 
of vascular injury. Normally, in response to ischemic insult and cytokine stimulation, 
endothelial progenitor cells are mobilized from the bone marrow to act as repair cells in 
response to the endothelial injury. In kidney disease there exists an impaired migratory 
activity and/or decreased numbers (Herbrig et al., 2004) of these cells, which may have a 
role in neovascularization of ischemic tissue and the progression of atherosclerosis and 
cardiovascular disease (Hill et al., 2003). Low levels of circulating endothelial progenitor 
cells predicted the occurrence of cardiovascular events and death. An imbalance between 
the expression of circulating endothelial cells (reflecting inflammatory endothelial damage) 
and endothelial progenitor cells (reflecting endothelial repair capacity) seems to exist in 
chronic kidney disease (Stenvinkel et al., 2008). This imbalance may contribute to the 
pathogenesis and progression of the atherosclerosis.  
In agreement with Stenvinkel et al., until the results of new studies regarding this issue 
become available, endothelial dysfunction should be considered a cardiovascular marker 
and not an etiological factor in kidney patients, intimately related to oxidative stress and 
inflammation (Stenvinkel et al., 2008).      
3.1 The endothelium and oxidative stress 
Under normal conditions, reactive oxygen species (which include various compounds such 
as superoxide anions, hydrogen peroxide, and hydroxyl radical) are produced in 
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mammalian cells during energy production in mitochondria by reducing oxygen during 
aerobic respiration (Pieczenik & Neustadt, 2007). In addition, a variety of enzymatic and 
nonenzymatic sources of reactive oxygen species exist in vascular vessels as well as different 
tissues, among which can be included nicotinamide dinucleotide (phosphate) (NAD(P)H 
oxidase enzyme complex, xanthine oxidase, lipoxygenases, and cyclooxygenases 
(Portaluppi et al., 2004). An uncoupling of nitric oxide synthase, owing to the reduction of 
its cofactor, BH4, can also contribute to oxygen metabolites (Andrew & Mayer, 1999). 
Reactive oxygen species levels are maintained at a normal range by scavenging through 
various antioxidant enzyme activities such as superoxide dismutase, catalase, glutathione 
peroxidase, and other components such as reduced glutathione, transition metal ions, and 
ascorbic acid. (Blokhina et al., 2003). Reactive oxygen species are part of the organism’s 
unspecified initial defense system. However, excessive reactive oxygen species levels can 
produce cellular damage by interacting with biomolecules; this imbalance, which the 
cellular components cannot bear long, is called oxidative stress.  
As mentioned, oxidative stress takes place when the production of oxidants exceeds local 
antioxidant capacity, resulting in the oxidation of proteins, lipids, carbohydrates, and DNA. 
Briefly, oxidative stress biomarkers can be classified as derived from lipids 
(malondialdehyde,  lipid hydroperoxides,  oxidized low-density lipoprotein,  advanced 
lipoxidation end products), arachidonic acid derivatives (F2 isoprostanes), carbohydrates 
(reactive aldehydes, advanced glycosylation end products), amino acids (cysteine/cystine, 
homocysteine/homocystine), proteins (carbonyl formation,  advanced oxidation protein 
products) and DNA (8 hydroxy 2’ deoxyguanine) (Himmelfarb et al., 2002).  Oxidative stress 
can occur via four different chemical pathways: Oxygen reactive species can lead to the 
production of advanced glycosilation end-products (carbonyl stress); to the inhibition of 
nitric oxide synthase (nitrosative stress); to the production of hydrogen peroxide and 
chlorine hydroxide (chlorinated stress); and to the generation of hydroxide species with the 
intervention of iron molecules (classical oxidative stress). Definitively, chlorinated stress is 
the most important pathway implicated in renal failure (Massy et al., 2003; Himmelfarb et 
al., 2001). 
Uremia is a prooxidant state. Lipid peroxidation, oxidative modification of proteins and 
carbohydrates and certain uremic toxins themselves have been implicated in endothelial 
dysfunction in chronic renal disease (Himmelfarb et al., 2002; Linden et al., 2008; Oberg et 
al., 2004; Trimarchi et al., 2003). Moreover, numerous defects in antioxidant systems lead to 
a decrease in the depuration of reactive oxygen species. Oxidative stress appears to start 
early in chronic kidney disease (Oberg et al., 2004), but total antioxidant capacity has been 
observed to be excelled only in end-stage renal failure, suggesting that reactive oxygen 
species production start overcoming their clearance at the beginning of the decline in renal 
function. Finally, dialysis treatment may have contradictory effects on it, depending on the 
quality, modality, and duration of the procedure itself (Pupim et al., 2004; Hand et al., 1998; 
McGregor et al., 2003).   
Although priming of polymorphonuclear leukocytes is a prominent feature in chronic 
kidney disease (Hörl, 2002), and myeloperoxidase is involved in chlorinated stress, the exact 
role of inflammation as a trigger of oxidative stress remains poorly defined in renal disease. 
As suggested, longitudinal studies of patients with mild chronic kidney disease are needed 
to resolve the issue of which is the initial culprit: inflammation or oxidative stress 
(Stenvinkel et al., 2008).  
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Oxidative stress in the kidney and vascular tissues can elevate arterial pressure via several 
mechanisms. Reactive oxygen species react with and inactivate nitric oxide; it also perturbs 
its production production by depleting the nitric oxide synthase cofactor 
tetrahydrobiopterin; and it contributes to accumulation of asymmetrical dimethylarginines, 
which in turn curtails nitric oxide production. Reduced bioavailability of nitric oxide, as a 
resultant of endothelial dysfunction, enhances the development and maintenance of 
hypertension by augmenting systemic vascular resistance, by increasing adrenergic tone, 
volume expansion and vascular smooth muscle cell proliferation, matrix accumulation and 
vascular remodeling, which are inhibited by nitric oxide and and promoted by free radicals 
(Wilcox, 2005). Another mechanism by which oxidative stress can cause hypertension and 
atherogenesis in renal failure is via nonenzymatic oxidation of arachidonic acid and 
formation of isoprostanes, which display vasoconstrictor, proinflammatory and 
antinatriuretic activity (Vaziri & Rodríguez-Iturbe, 2006; Schnackenberg, 2002). Finally, 
oxidative stress enhances the production of angiotensin II, which leads to increased blood 
pressure by promoting sodium retention and renal vasoconstriction (Navar et al., 2002). 
Moreover, oxidative stress increases production of endothelin-1 and the cytosolic 
concentration of calcium, thereby increasing vascular smooth muscle tone, systemic vascular 
resistance, arterial pressure and accumulation of matrix proteins (Kahler et al., 2001; Touyz, 
2005).  
3.2 The endothelium and inflammation 
In chronic kidney disease, a state of persistent low-grade inflammation is commonly 
observed. Chronic inflammation is characterized by the persistent effect of a causative 
stimulus, which leads to destruction of cells and tissues and has deleterious effects to the 
body. In chronic kidney disease, especially in stage 5, the systemic concentrations of both 
pro- and anti-inflammatory cytokines are several-fold higher as a result of both decreased 
renal clearance and increased production. Several factors, both dialysis-related (e.g., 
membrane bioincompatibility) and non–dialysis-related (e.g., infection, comorbidity, genetic 
factors, diet), may additionally contribute to a state of persistent inflammation. In addition 
to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst 
and, in the uremic milieu, modulate the effects of risk factors for wasting and vascular 
disease (Carrero & Stenvinkel, 2009). In the uremic milieu, in which cytokines are retained 
as a result of loss of residual renal function and stimulated by comorbidities and the dialysis 
procedure itself, such interactions should be of relevance. 
As mentioned before, elevated C-Reactive Protein is associated with atherogenesis and 
endothelial dysfunction, and inflammation enhances cardiovascular risk and mortality in 
haemodialysis patients (Zimmermann et al., 1999). Tumor necrosis factor-alpha is increased 
in this process, and may synergize oxidative stress processes that lead to lipid peroxidation 
and oxidized LDL (Stenvinkel et al., 1999). Inflammation also might cause endothelial 
dysfunction through the stimulation of intracellular adhesion molecules in patients with 
chronic kidney disease as soluble Vascular Adhesion Molecule-1 (sVCAM-1) and soluble 
Intercellular Adhesion Molecule-1 (sICAM-1) (Stam et al., 2003).  
Migration of monocytes into the vessel wall contributes to the onset and progression of 
atherosclerosis (Kon et al., 2011). The infiltration of monocytes and T lymphocytes in the 
vascular wall depends on the response to chemokines, and CD142+CD16+ monocytes are 
characterized by a unique pattern of chemokine receptors, represented by the chemokine 
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receptor 5 (CCR5). In states of inflammation, CCR5 could contribute to atherogenesis 
through the binding of its ligands, which in turn mediate the recruitment of inflammatory 
cells to the endothelium (Carrero & Stenvinkel, 2009).  
Chronic kidney disease is a low-grade inflammatory process with peripheral 
polymorphonuclear leukocyte and CD14+/CD16+ cells being key mediators in this process 
(Sela et al., 2005).  In fact, persistent inflammation may also be a risk factor per se for 
progression of kidney disease, as inflammatory markers are predictors of kidney function 
deterioration. This could be a consequence of inflammatory mediators such as tumor 
necrosis factor-alpha or interleukin-6 being able to act as toxins participating in uremia 
complications. In addition, C-Reactive protein formed locally in the renal inflammatory 
process reduces nitric oxide production, stimulates endothelin-1 formation, and induces 
some of the steps involved in the atherosclerosis process, as monocyte recruitment and foam 
cell formation (Labarrere & Zaloga, 2004). Elevated C-Reactive protein, interleukin-6, and 
fibrinogen are independent predictors of cardiovascular outcomes in patients with kidney 
disease (Cachofeiro et al., 2008). Inflammation could promote both renal deterioration 
(triggering endothelial dysfunction, atherosclerosis, and glomerular injury) and 
cardiovascular mortality. Inflammation is a redox-sensitive mechanism, as oxidative stress is 
able to activate transcriptor factors such as Nuclear Factor-kappaB, which regulates 
inflammatory mediator gene expression (Li & Karin, 1999). This nuclear factor is maintained 
inactivated in the cytoplasm by binding to inhibitory proteins. Their phosphorylation, 
posterior ubiquitination, and proteolysis result in the release and translocation of it to the 
nucleus and consequent activation of specific genes. Some of these steps seem to be affected 
by oxidative stress as the presence of antioxidants prevents nuclear factor-kappaB activation 
by reactive oxygen species (Li & Karin, 1999).  
The observation that both protein-energy wasting and persistent inflammation are highly 
prevalent in dialysis patients and are associated with a substantially increased mortality risk 
has focused on the endothelium as an important target (Carrero & Stenvinkel, 2009). 
Because protein-energy wasting, inflammation, and atherosclerosis often coexist in the 
uremic milieu, these risk factors are linked. One of the main detrimental effects of 
proinflammatory cytokine activation in patients with end-stage renal disease is muscle 
depletion or sarcopenia, mediated by interleukin-6, angiotensin II and Tumor Necrosis 
Factor –like weak inducer of apoptosis (TWEAK) (Carrero et al., 2008).  
The role of persistent inflammation as a culprit of converting the endothelium into a 
procoagulant and proinflammatory surface that makes the vasculature more vulnerable to 
the effects of other circulating risk factors is to be better determined. However, the strong 
associations between inflammatory markers and endothelial dysfunction in patients with 
chronic kidney disease support this hypothesis (Carrero & Stenvinkel, 2009). 
3.3 The endothelium and uremic toxins  
During the development of the uremic syndrome, losses of kidney function are 
accompanied by deteriorating organ function attributable to the accumulation of uremic 
retention solutes. Compounds that exert an adverse biologic impact are called uremic toxins. 
At least 115 toxins accumulate in uremia and may play an important role in the 
pathogenesis of the uremic sindrome (Vanholder et al., 2008). Peptides in the 10- to 30-kD 
range, for example, are some of the so-called “middle molecules.” These peptides can be 
glycosylated, oxidized, or carbamylated, thereby altering their structure and function so that 
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cell and organ dysfunction may not simply result from accumulation of these metabolites. 
Uremic toxins provoke oxidative stress, inflammation, hypertrophy, constriction, and 
coagulation through various mechanisms. Monocytes, in response to advanced 
glycosylation end products that accumulate in uremia, produce free radicals that provoke 
oxidative stress. Monocytes, in response to leptin accumulation in uremia, cause clotting. 
Macrophages in response to homocysteine provokes oxidative stress. Finally, leukocytes are 
activated by the uremic toxin p-cresol sulfate. Platelets now are recognized to accumulate 
uremic toxins, and the interaction between platelets and vascular smooth muscle may lead 
to vascular smooth muscle growth and constriction, thereby contributing to both 
hypertension and atherosclerosis. The uremic toxins in platelets are collectively known as 
diadenosine polyphosphate. Both diadenosine pentaphosphate and diadenosine 
hexaphosphate are strongly protein bound and poorly removed by dialysis and produce 
vasoconstriction or vascular smooth muscle growth (Vanholder et al., 2010). Uremic toxins 
can activate the endothelium to produce the following effects: (1) vasoconstriction (via 
asymmetric dimethylarginine, advanced glycation end product, and homocysteine); (2) 
inflammation (via indoxyl sulfate and advanced glycation end products); (3) oxidative stress 
(via asymmetric dimethylarginine, advanced glycation end product, and homocysteine); (4) 
or procoagulant activity. The procoagulant effect of endothelium is noted by increased 
procoagulant factors (increased plasminogen activator inhibitor-1 and von Willebrand 
factor) and reduced anticoagulant factors (e.g., tissue plasminogen activator). It follows, 
then, that a diverse group of toxins act on a variety of cell types to provoke oxidative stress, 
inflammation, vascular smooth vessel proliferation and constriction, endothelial 
dysfunction, and coagulation, accounting for some of the manifestations of the uremic 
syndrome that include hypertension and accelerated atherosclerosis.  
These low molecular weight organic compounds may either exist in free water- soluble 
forms or bind reversibly to serum proteins, thereby altering protein functions (Vanholder et 
al., 1992). In kidney disease, peptides may be found in their native form or, as a consequence 
of exposure to the uremic milieu, become irreversibly altered resulting in changes in 
structure and function. Importantly, both protein-bound solutes and peptides are 
particularly difficult to remove by conventional dialysis treatments, and uremic retention 
solutes may play a role in uremia-related complications (Vanholder et al., 2008). There have 
been described dual effects of uremic retention solutes on leukocyte function: Blunting upon 
stimulation, which has been linked to infection, and basal activation linked to 
microinflammation, malnutrition, and atherosclerosis. The major leukocyte subtypes 
affected by uremic conditions are polymorphonuclear cells, specifically neutrophils and 
mononuclear cells of the monocyte/macrophage type 2. It is predominantly the latter cell 
type that is activated by uremic retention solutes, enhancing vascular damage (Vanholder et 
al., 2008). 
Patients on haemodialysis have alterations in endothelial properties with increases in both 
plasminogen activator inhibitor-1 and von Willebrand factor, whereas tissue plasminogen 
activator decreases, suggesting a procoagulant state at the endothelial surface (Haaber et al., 
1995). Regulation of vascular tone is also impaired with decreased endothelium-dependent 
vasodilatation, associated with the aforementioned inhibition of endothelial nitric oxide 
synthase by asymmetric dimethylarginine, advanced glycation end-products and 
homocysteine.  Chronic kidney disease also induces oxidant stress and inflammation in 
endothelial cells and production of reactive oxygen species in cultured endothelial cells by 
the protein-bound uremic toxin indoxyl sulfate. 
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A new insight into endothelial dysfunction is also provided by the observation of circulating 
endothelial microparticles. The generation of endothelial microparticles is elicited in vitro by 
the presence of indoxyl sulfate (Faure et al., 2006). A remarkable characteristic of the 
endothelium is its capacity for continuous regeneration and repair. This involves two 
mechanisms: The classically described proliferation of adjacent endothelial cells and the 
more recently described homing of circulating endothelial progenitor cells (Vanholder et al., 
2008). These latter cells may be mobilized from bone marrow in response to cytokines or 
ischemia or derive from circulating leukocytes. In haemodilaysis subjects, endothelial repair 
mechanisms are altered, representing a possible threat to vascular integrity. Some uremic 
toxins such as indoxyl sulfate reduce endothelial proliferation, and serum from uremic 
patients decreases the ability of endothelial progenitor cells to migrate. In addition, these 
patients generally have a decrease in the number of circulating endothelial progenitor cells 
(de Groot et al., 2004). 
3.4 The endothelium and haemostatic disturbances 
An important intermediary in the continued activation of endothelial cells is the interaction 
of the endothelium with platelets . The adhesion of platelets to activated endothelial cells is 
mediated by a glycoprotein IIb/IIIa-dependent mechanism. The activation of glycoprotein 
IIb/IIIa induces the expression of factors such as P-selectin  that promote activation of the 
endothelium (May et al., 2002). Platelets recruit bone marrow-derived progenitor cells to the 
activated endothelium and the injured vessel wall by providing a surface that supports 
interaction between platelet P-selectin and the glycoprotein IIb/IIIa integrin (Rabelink et al., 
2010). A relevant platelet-derived chemokine for the interaction of leukocytes with the 
activated endothelium is RANTES, secreted by thrombin-stimulated platelets and 
immobilized on the surface of the inflamed endothelium which triggers shear stress-
resistant monocyte arrest. (von Hundelshausen & Weber, 2007). After their activation, 
membrane vesicles (0.1–1 μm in diameter) may be released from endothelial cells. Under 
normal conditions, phospholipid moieties in the plasma membrane are distributed 
asymmetrically. During microparticle formation, membrane asymmetry is lost, resulting in 
microparticles becoming procoagulant. (Rabelink et al., 2010). A variety of proinflammatory 
agents, including tumor necrosis factor, and procoagulant factors, such as thrombin, can 
induce the formation of endothelial microparticles. The biological effects of endothelial 
microparticles are largely determined by their protein and lipid composition. They might 
contain tissue factor, metabolic enzymes, proteins involved in adhesion and fusion 
processes, cytoskeleton associated proteins, or chemokines. Endothelial microparticles 
themselves can therefore contribute to the further activation of endothelial cells and to the 
initiation of coagulation, and may transfer endothelial proteins to circulating cells. 
Circulating levels of endothelial microparticles have been suggested to be a marker of 
sustained endothelial-cell activation. These circulating microparticles are elevated in dialysis 
patients (Mallat et al., 2000), and could be directly related to the presence of uremic toxins 
(Rabelink et al., 2010). The levels of endothelial microparticles in patients with end-stage 
renal disease positively correlate with endothelial dysfunction, as measured by flow-
mediated vasodilatation, and indices of arterial stiffening. Endothelial microparticles 
directly impair endothelium-dependent vasodilator mechanisms in dialysis subjects, while 
their low levels are associated with improved survival in this population. As mentioned 
before, platelets also play a central role in vascular damage by inducing haemostasis and 
arterial thrombosis (Vanholder et al., 2010).  
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As discussed previously, platelets interact with coagulation factors, in particular thrombin, 
and during thrombin-induced aggregation, almost the entire content of platelet granules is 
released. Platelets from patients with renal failure have increased intracellular concentration 
of the diadenosine polyphosphates which act as strong growth factors for vascular smooth 
muscle cells. Because enhanced smooth muscle growth is a hallmark of atherosclerosis in 
renal failure, the increased amount of diadenosine polyphosphates in platelets may play an 
important role in causing increased cardiovascular damage. Furthermore, diadenosine 
polyphosphates are strong vasoconstrictors with direct effects on vascular tone (Vanholder 
et al., 2010). Thus, platelet-endothelium interaction may play an important role in 
hypertension and atherosclerosis in renal failure. 
3.5 The endothelium and protein-energy wasting 
There has been an increase of mechanisms causing syndromes of wasting, malnutrition, 
inflammation, and their interrelationships in individuals with chronic kidney disease.  
Approximately 18–75% of patients on chronic dialysis show evidence of wasting (Stenvinkel 
et al., 2004). This phenomenon has been referred to as uremic malnutrition, uremic cachexia, 
protein–energy malnutrition, malnutrition–inflammation atherosclerosis syndrome, or 
malnutrition–inflammation complex syndrome (Fouque et al., 2008). Many of the measures 
indicating the presence of wasting and abnormalities in protein–energy nutritional status 
can also be induced by inflammatory processes. As mentioned in previous sections, an  
increase in proinflammatory cytokines may cause loss of protein stores. The loss of muscle 
and fat stores and the present inflammation condition are likely to increase the risk of death 
from cardiovascular disease by promoting endothelial damage (Avesani et al., 2006). In 
kidney disease, there are conditions resulting in loss of lean body mass not related to 
reduced nutrient intake, due to nonspecific inflammatory processes, intercurrent catabolic 
illnesses, nutrient losses into dialysate, academia, resistance to anabolic hormones, 
hyperglucagonemia, hyperparathyroidism, use of prostheses, and anemia or its treatment 
(Fouque et al., 2008). Amongst the number of disorders that can cause wasting in patients 
with kidney disease, inflammation, oxidative stress, acidemia, nutrient losses into dialysate, 
anemia, hyperparathyroidism, and retention of uremic toxins interplay and, as shown in 
previous sections, cause endothelial dysfunction, leading to atherogenesis and 
cardiovascular disease). Elevated cardiovascular and haemodynamic markers of disease and 
endothelial stress as Pro-Brain Natriuretic Peptide or Troponin T are associated with 
wasting and inflammation in haemodialysis subjects. The employment of vascular 
prostheses and catheters may play a role in this abnormal setting (Trimarchi et al., 2011).   
3.6 The endothelium, anemia and erythropoiesis-stimulating agents 
The association of anemia with cardiovascular outcomes is well known, but underlying 
mechanisms are not well understood (Jurkovitz et al., 2003). However, targeting a higher 
hemoglobin with higher doses of erythropoiesis-stimulating agents worsens cardiovascular 
outcomes in dialysis individuals (Singh et al., 2006) Possibilities include a higher 
prothrombotic state due to hypercoagulability  or a potentially toxic effect of erythropoietic 
agents on the cardiovascular system.(Keithi-Reddy et al., 2008) As commented before, there 
exists a role for inflammation in atherosclerosis in kidney subjects. There is recent evidence 
that tumor necrosis factor-alpha is higher and the levels of serum albumin lower in anemic 
compared to non-anemic dialysis subjects. The levels of interleukins -6 and -8, display 
increasing trends between anemic and non-anemic patients (Keithi-Reddy et al., 2008). 
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These cytokines have been implicated as non-traditional cardiovascular risk factors 
associated with an increased risk of atherosclerosis. Interleukin-6  stimulate production of C-
Reactive protein, while interleukin-8 is a potent angiogenic factor that induces migration 
and proliferation of endothelial cells and smooth muscle cells contributing to plaque 
formation in atherosclerosis. (Simonini et al, 2000).  One of the hypotheses promulgated to 
explain increased inflammation in chronic kidney disease patients is the reduced clearance 
of cytokines as renal function declines. Inflammatory cytokines interfere with both 
proliferation and differentiation of erythroid precursors by several mechanisms, including 
induction of apoptosis, downregulation of erythropoietin receptors, and reduced activity 
and synthesis of them (Weiss & Goodnough, 2005). Besides, states of vascular congestion 
and chronic heart failure have been shown to have elevated levels of these inflammatory 
markers when the renal function declines. Of the inflammatory markers, interleukin-6 is 
important by virtue of its actions not only on cardiovascular system but also on worsening 
of anemia. 
However, the notion that oxygen transport capacity might increase at hematocrit values 
above 34% in patients with chronic renal disease is undetermined, because it has been 
known that when hematocrit values rise above 40% in normal subjects, oxygen transport 
capacity decreases as a result of the decrease in cardiac index associated with a rise in blood 
viscosity (Crowell & Smith, 1967). The optimal hematocrit in dialysis patients has not been 
defined but may be lower than that in normal subjects because of decreased arterial and 
ventricular compliances and impaired cardiac index. Two controlled predialysis studies 
(CHOIR and CREATE), which compared traditional hematocrit targets of 34% to fully 
normalized targets, reported either no improvement in quality of life or that increased 
erythropoietin dosing resulted in increased cardiovascular adverse events or hypertension 
(Singh et al., 2006). The mechanisms responsible for these excess cardiovascular and 
mortality events are not fully elucidated, but erythropoietin-stimulating agents-induced 
arterial hypertension is a candidate (Krapf & Hulter, 2009). The increase in systolic and 
diastolic blood pressure at the target hematocrit varied but reached an average of 
approximately 5 to 8 mmHg in systolic and 4 to 6 mmHg in diastolic blood pressure. 
Erythropoietin doses of 40, 80, and 120 U/kg thrice weekly for 49 weeks were associated 
with hypertension in 28%, 32%, and 56% of treated subjects, respectively (Krapf & Hulter, 
2009). Erythropoietin induced hypertension is independent of its effect on red blood cell 
mass and viscosity is supported by the demonstration in rats that coadministration of 
erythropoietin with either a synthetic erythropoietin binding protein or an anti-
erythropoietin antibody prevented erythropoietin-induced hypertension while preserving 
the erythropoietic response. This suggests the interesting possibility that different epitopes 
on the erythropoietin protein confer independent erythropoietic and haemodynamic effects. 
Erythropoietin induces endothelin-1 release and produces an enhanced mitogenic response 
in endothelial cells (Krapf & Hulter, 2009). Production of the vasodilating prostacyclin is 
decreased and the vasoconstricting prostanoid thromboxaneB2 is increased. In human 
endothelial cells, erythropoietin decreases e nitric oxide synthase expression resulting in 
decreased endothelial nitric oxide production. The mechanism may include increased 
production of reactive oxygen species and asymmetric dimethylarginine (Scalera et al., 
2005). A systemic effect to blunt endothelial nitric oxide production, combined with the 
increased endothelin-1 response and predominance of thromboxane over prostacyclin could 
explain the erythropoietin-induced vasoconstrictive effect (Krapf & Hulter, 2009). Moreover, 
at least a subset of haemodialyzed patients exhibit an accentuated hypersensitivity to 
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angiotensin II and norepinephrine during erythropoietin treatment, which correlated with 
an increase in blood pressure (Krapf & Hulter, 2009). Thus, erythropoietin-induced 
hypersensitivity to angiotensin II and norepinephrine, as well as increased endothelin-1 
activity, are reasonable mechanisms for erythropoietin-induced hypertension in 
haemodialyzed patients, in part impairing endothelial relaxation (Annuk et al., 2006). 
Interestingly, anemic patients treated with erythropoietin compared to erythropoietin-naive 
patients revealed increased levels for interleukins-6 and -8, C-Reactive protein, and tumor 
necrosis factor-alpha. Although the antiapoptotic effect of erythropoietin on erythroid 
precursors in the bone marrow is well described, its potential effect of on cytokines is less 
well understood (Krantz, 1991). Long-term administration of erythropoietin has been 
associated with decreased levels of tumor necrosis-alpha in subjects on haemodialysis, but 
also to enhance inflammation and ischemia-induced neovascularization by increasing the 
mobilization of endothelial progenitor cells (Heeschen, et al., 2003). Furthermore, 
erythropoietin activates vascular smooth muscle cells, endothelium, and platelets enhancing 
thrombogenity and loss of vasodilatory potential. An alternative hypothesis is that 
induction of proinflammatory cytokines by erythropoietin occurs as a consequence of  
acting via erythropoetin receptors on macrophages, which upon activation secrete 
interleukin-6,-8, and tumor necrosis-alpha, leading to chronic inflammation, protein-energy 
wasting and atherogenesis. Indeed, these molecules have been associated with an increased 
risk of death in the dialysis population ( Keithi-Reddy et al., 2008). In addition, this could be 
one explanation for the observation of increased risk for all-cause and cardiovascular 
mortality in patients targeted to higher hemoglobin levels with higher doses of 
erythropoiesis stimulating  agents (Singh et al., 2006) 
3.7 The endothelium and vascular calcification and ossification 
Vascular calcification is responsible for the higher prevalence of cardiovascular disease in 
dialysis patients. Consequently, its early detection is truly relevant in this population. 
Traditionally, it has been described as a patchy-like and/or a linear calcification that 
corresponds to intima (atherosclerosis-related) and media calcification (related to 
calcium/phosphorus disturbances). However, there is a current debate about the location of 
calcium in the artery wall and their clinical implications, as referred before (Coll et al., 2011). 
Calcified plaques and intima calcification appear to be the most prevalent coronary 
abnormalities in advanced chronic kidney disease patients, and only a small proportion 
present media calcification. The pattern of linear calcification is highly associated with 
atherosclerosis (Coll et al., 2011). Vascular calcification has been historically classified as (1) 
intima calcification associated with atheroma plaques and (2) medial calcification mediated 
by a switch of vascular smooth muscle cells to a procalcification phenotype and associated 
with kidney disease and disturbances in the metabolism of calcium, phosphorus, and 
vitamin D (Cardús et al., 2006). However several potential flaws associated with this 
traditional view present: First, large arteries are “elastic” arteries functioning as blood 
conduits, and as such have a low content of smooth muscle cells. On the contrary, small, 
peripheral arteries are aimed at the regulation of blood flow in the tissue, presenting a dense 
layer of smooth muscle cells. Traditionally it is stated that large arteries are more prone to 
atherosclerosis, while small vessels are more prone to calcify. Moreover, the anatomic 
location of calcium in the artery wall presents a singular pattern that corresponds to the 
calcification of the internal elastic lamina. Conversely, medial calcification is related to the 
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control of metabolic disturbances in terms of calcium, phosphorus, and vitamin D. 
However, low serum phosphorus is a protective factor for developing linear calcification, 
underscoring the influence of phosphorus on atherosclerosis. Therefore, vascular 
calcification in large arteries is more prevalent in dialysis patients than in controls, and it is 
predominantly a linear pattern located in the lumen-intima interphase. Age, dialysis, past 
medical history of cardiovascular disease, atherosclerosis, and inflammation are variables 
significantly influencing calcification (Coll et al., 2011). 
Recently, the term ossification rather than calcification of  both the arterial intima and media 
has been proposed for kidney subjects (Stenvinkel et al., 2008). The presence of artery 
ossification is associated with functional estimates of arterial dysfunction, such as nitric 
oxide-dependent vasodilatation in dialysis patients and pulse-wave velocity (Raggi et al., 
2007). Vascular ossification should be considered as a cardiovascular risk marker and not an 
etiological factor of cardiovascular disease in chronic kidney disease (Stenvinkel et al, 2008). 
Multiple new biomarkers for early detection of arterial intima and/or media ossification 
have emerged. Serum levels of calcium and phosphorus have become established risk 
markers (Block et al., 2005). Hyperparathyroidism has also been suggested as a risk factor 
for and a marker of vascular ossification (Stevens et al., 2004), and Vitamin D deficiency is 
associated with increased early mortality. The best studied inhibitor of vascular ossification 
is fetuin-A, the major carrier of calcium ions in the circulation. Only in chronic kidney 
patients stage 5 low levels of fetuin-A are associated with adversed cardiovascular outcomes 
(Hermans et al., 2007). The ossification regulators matrix-Gla protein, bone morphogenic 
proteins, osteopontin, and osteoprotegerin, promote an early and extensive vascular 
ossification process, and have been shown to interfere with endothelial function by 
decreasing nitric oxide production and altering the normal anatomic vessel wall, rendering 
the endothelial surface prone to calcium deposition, prothrombotic events and a more rigid 
vessel wall (Hofbauer et al., 2007). 
4. The endothelium and haemodialysis 
Endothelial dysfunction is the initial pathophysiologic step in the progression of vascular 
damage that precedes and leads to clinically manifest cardiovascular diseases (Vita & 
Keany, 2002). Endothelial dysfunction is highly prevalent in patients with advanced chronic 
kidney disease (Endermann & Schiffrin, 2004) and is linked to the elevated cardiovascular 
risk of this patient population (Tonelli & Pfeffer, 2007). The cause of endothelial dysfunction 
is complex and involves dysregulation of multiple pathways (Yilmaz et al., 2009). 
4.1 Haemodialysis components and endothelial damage 
Haemodialysis therapy may induce activation of complement and polymorphonuclear 
leukocytes, monocytes, or lymphocytes, depending on the dialyzer membrane used. The 
clinical situation is further complicated by the accumulation of uremic retention solutes and 
toxins, often inadequately removed during the dialysis schedule. Haemodialysis patients 
display evidence of elevated interleukin-1 and tumor necrosis factor-alpha release, which is 
followed by the stimulated secretion of interleukin-6, responsible for acute-phase protein 
synthesis. High levels of the circulating proinflammatory cytokines interleukins-1, -6, -13 
and tumor necrosis factor-alpha are associated with mortality in hemodialysis patients 
(Hörl, 2002). Essential functions of polymorphonuclear leukocytes—that is, phagocytosis, 
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oxygen species production, upregulation of specific cell surface receptor proteins, or 
apoptosis—are disturbed in uremia. Clinical signs and symptoms of end-stage renal disease 
patients are at least in part related to the accumulation of middle molecules such as beta 2-
microglobulin, parathyroid hormone, advanced glycation end products, advanced 
lipoxidation end products, advanced oxidation protein products (formed as a result of 
oxidative stress, carbonyl stress, or both), granulocyte inhibitory proteins, or leptin. 
Currently available membrane materials do not provide long-lasting, effective reduction of 
middle molecules in patients who require maintenance haemodialysis (Hörl, 2002).  
During haemodialysis, contact of blood with the dialyzer and dialysate also activates the 
kallikrein-kinin system and also induces the above mentioned inflammatory response. 
(Marney et al, 2009). These cytokines stimulate plasminogen activator inhibitor-1, the major 
physiologic inhibitor of fibrinolysis. Activation of the kallikrein-kinin could have favorable 
or deleterious effects on inflammation and the risk of cardiovascular events through 
endothelial damage. First, bradykinin causes vasodilation and stimulates the release of 
tissue-plasminogen activator from the endothelium, and infused bradykinin inhibits platelet 
aggregation. Conversely, bradykinin stimulates the inflammatory response and may have 
implications in atherothrombotic events in hemodialysis. Endogenous bradykinin 
contributes to hypotension, increased inflammation, increased oxidative stress, and 
increased fibrinolysis in response to haemodialysis (Marney et al., 2009).  
Enhanced production of proinflammatory cytokines by dialysate pyrogens, by complement 
activation, or both, as well as inhibition of anti-inflammatory cytokine secretion, may 
contribute to the cell-mediated immunosuppression seen in dialysis patients. The presence 
of low and high molecular weight inhibitors of neutrophils in the plasma of uremic patients 
may explain, at least in part, why infections are a common cause of hospitalization and the 
second most common cause of death in these patients. Other middle molecules accumulate, 
and proteins are modified by oxidative stress, carbonyl stress, or both, contributing to the 
uremic syndrome. 
4.2 Haemodialysis and endothelial function improval  
Dialysis patients frequently present with endothelial dysfunction and a higher risk of 
developing atherosclerosis. Factors that impair endothelial function include lipid 
abnormalities, hyperhomocysteinemia, and the accumulation of inhibitors of nitric oxide 
synthesis (Trimarchi et al., 2002). Endothelial dysfunction can be detected long before 
atherosclerosis arises (Vanhoutte, 1988), and on ocassions can be improved by appropriate 
haemodialysis delivery (McGregor et al., 2003). Haemodialysis itself can reduce plasma 
endothelin-1 levels and increase the vasodilator endothelium-derived adrenomedullin 
(McGregor et al., 2003), which vasodilatory action is in part nitric oxide dependent (Majid et 
al., 1996). Asymmetric dimethyl-arginine, the nitric oxide antagonist that is elevated in 
uremia, can be cleared by dialysis (McGregor et al., 2003).  
One of the most serious haemodynamic complications of uremia is hypotension. 
Symptomatic hypotension occurs in approximately 25% of haemodialysis sessions, and can 
restrict the amount of fluid to be removed. Many mechanisms have been proposed: 
Abnormalities of the response of resistance and capacitance vessels to hypovolemia and 
disbalanced reflex increases in peripheral vascular resistance to hypovolemia have been 
implicated (Hand et al., 1998). The endothelium adequate response is also altered by the 
uremic toxins that accumulate and by the abnormal cellular and chemical reactions between 
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platelets, leukocytes and the endothelial cell itself. When appropriately performed and 
delivered, haemodialysis sessions may improve endothelial function by improving the 
internal milieu and by removing the toxins and inflammatory mediators that can interfere 
with the normal endothelium-derived vasomodulator activity (Hand et al., 1998, McGregor 
et al., 2003), albeit some studies have failed to support this finding (Pupim et al., 2004). 
Finally, as endothelial cells are highly sensitive to extracellular sodium and potassium, the 
chemical derangement that rules in renal failure alters the endothelial-mediated regulation 
of local blood flows. This effect may also has pathophysiological relevance in the 
development of hypertension and atherosclerosis in haemodialysis subjects (Oberleithner et 
al., 2010). 
5. Conclusions 
The endothelium is a vital organ that dynamically interacts with the whole economy, 
managing vital activities through the mediators it synthesizes and releases in an endocrine 
and paracrine fashion. It plays a main role in vascular tone and metabolic pathways. In 
haemodialysis, endothelial dysfunction can be caused by several factors or worsen them: 
Oxidative stress, inflammation, haemostatic derangements, protein-energy wasting, 
vascular calcification, anemia, molecular alterations and the dialytic procedure itself. They 
are strongly interrelated and play a major role in the initiation and progression of vascular 
complications, leading to the high mortality rate cardiovascular disease presents in dialysis. 
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